Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;44(5):387-95.
doi: 10.1016/j.ijantimicag.2014.08.002. Epub 2014 Sep 2.

Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci

Jose M Munita  1 , Barbara E Murray  2 , Cesar A Arias  3
Affiliations
Review

Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci

Jose M Munita et al. Int J Antimicrob Agents. 2014 Nov.

Abstract

Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE.

Keywords: Daptomycin; Enterococcal bacteraemia; Enterococci; VRE.

PubMed Disclaimer

Conflict of interest statement

Competing interests: BEM has received grants from Johnson & Johnson, Cubist, Theravance and Forest, personal fees from Theravance, and personal fees and non-financial support from Rib-X, Durata Therapeutics, Achaogen, The Medicines Co. and GlaxoSmithKline; CAA has received grants from Forest Pharmaceuticals, Theravance Inc. and Pfizer, consulting fees from Cubist, Novartis, AstraZeneca, Pfizer, Bayer Inc. and Theravance Inc. and has served as speaker for Pfizer, Forest Pharmaceuticals, Novartis, AstraZeneca and Cubist. JMM declares no competing interests.

References

    1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29:996–1011. - PubMed
    1. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10:266–78. - PMC - PubMed
    1. Geraci JE, Martin WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases. Circulation. 1954;10:173–94. - PubMed
    1. Robbins WC, Tompsett R. Treatment of enterococcal endocarditis and bacteremia; results of combined therapy with penicillin and streptomycin. Am J Med. 1951;10:278–99. - PubMed
    1. Jawetz E, Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Science. 1950;111:254–6. - PubMed

Publication types

MeSH terms